Global Prostate Cancer Diagnostics Market Analysis and Forecast 2024-2030
Summary
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Prostate Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Prostate Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Prostate Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Prostate Cancer Diagnostics segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Prostate Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Prostate Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Prostate Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Prostate Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.
Prostate Cancer Diagnostics segment by Company
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
- Age Below 55
- Age 55-75
- Age Above 75
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Prostate Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Prostate Cancer Diagnostics Market by Type
1.2.1 Global Prostate Cancer Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 Prostate Cancer Diagnostics Market by Application
1.3.1 Global Prostate Cancer Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Age Below
1.3.3 Age 55-75
1.3.4 Age Above
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
2.1 Prostate Cancer Diagnostics Industry Trends
2.2 Prostate Cancer Diagnostics Industry Drivers
2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
2.4 Prostate Cancer Diagnostics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
3.2 Global Prostate Cancer Diagnostics Growth Trends by Region
3.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Prostate Cancer Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Prostate Cancer Diagnostics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Prostate Cancer Diagnostics Revenue by Players
4.1.1 Global Prostate Cancer Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Prostate Cancer Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
4.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
4.5 Global Prostate Cancer Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier
5 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY TYPE
5.1 Global Prostate Cancer Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Prostate Cancer Diagnostics Revenue by Type (2019-2030)
5.3 Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2030)
6 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY APPLICATION
6.1 Global Prostate Cancer Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Prostate Cancer Diagnostics Revenue by Application (2019-2030)
6.3 Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 OPKO
7.1.1 OPKO Comapny Information
7.1.2 OPKO Business Overview
7.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
7.1.5 OPKO Recent Developments
7.2 Genomic Health
7.2.1 Genomic Health Comapny Information
7.2.2 Genomic Health Business Overview
7.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
7.2.5 Genomic Health Recent Developments
7.3 Abbott
7.3.1 Abbott Comapny Information
7.3.2 Abbott Business Overview
7.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
7.3.5 Abbott Recent Developments
7.4 Beckman Coulter
7.4.1 Beckman Coulter Comapny Information
7.4.2 Beckman Coulter Business Overview
7.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
7.4.5 Beckman Coulter Recent Developments
7.5 Siemens Healthcare
7.5.1 Siemens Healthcare Comapny Information
7.5.2 Siemens Healthcare Business Overview
7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
7.5.5 Siemens Healthcare Recent Developments
7.6 bioMeriux
7.6.1 bioMeriux Comapny Information
7.6.2 bioMeriux Business Overview
7.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
7.6.5 bioMeriux Recent Developments
7.7 Roche
7.7.1 Roche Comapny Information
7.7.2 Roche Business Overview
7.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
7.7.5 Roche Recent Developments
7.8 MDx Health
7.8.1 MDx Health Comapny Information
7.8.2 MDx Health Business Overview
7.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
7.8.5 MDx Health Recent Developments
7.9 DiaSorin
7.9.1 DiaSorin Comapny Information
7.9.2 DiaSorin Business Overview
7.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
7.9.5 DiaSorin Recent Developments
7.10 Myriad Genetics
7.10.1 Myriad Genetics Comapny Information
7.10.2 Myriad Genetics Business Overview
7.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
7.10.5 Myriad Genetics Recent Developments
7.11 Ambry Genetics
7.11.1 Ambry Genetics Comapny Information
7.11.2 Ambry Genetics Business Overview
7.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
7.11.5 Ambry Genetics Recent Developments
8 NORTH AMERICA
8.1 North America Prostate Cancer Diagnostics Revenue (2019-2030)
8.2 North America Prostate Cancer Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Prostate Cancer Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Prostate Cancer Diagnostics Revenue by Type (2025-2030)
8.3 North America Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Prostate Cancer Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Prostate Cancer Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Prostate Cancer Diagnostics Revenue by Application (2025-2030)
8.5 North America Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Prostate Cancer Diagnostics Revenue by Country
8.6.1 North America Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Prostate Cancer Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Prostate Cancer Diagnostics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Prostate Cancer Diagnostics Revenue (2019-2030)
9.2 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Prostate Cancer Diagnostics Revenue by Type (2025-2030)
9.3 Europe Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Prostate Cancer Diagnostics Revenue by Application (2025-2030)
9.5 Europe Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Prostate Cancer Diagnostics Revenue by Country
9.6.1 Europe Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Prostate Cancer Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Prostate Cancer Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Prostate Cancer Diagnostics Revenue (2019-2030)
10.2 China Prostate Cancer Diagnostics Revenue by Type (2019-2030)
10.2.1 China Prostate Cancer Diagnostics Revenue by Type (2019-2024)
10.2.2 China Prostate Cancer Diagnostics Revenue by Type (2025-2030)
10.3 China Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
10.4 China Prostate Cancer Diagnostics Revenue by Application (2019-2030)
10.4.1 China Prostate Cancer Diagnostics Revenue by Application (2019-2024)
10.4.2 China Prostate Cancer Diagnostics Revenue by Application (2025-2030)
10.5 China Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Prostate Cancer Diagnostics Revenue (2019-2030)
11.2 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Prostate Cancer Diagnostics Revenue by Type (2025-2030)
11.3 Asia Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Prostate Cancer Diagnostics Revenue by Application (2025-2030)
11.5 Asia Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Prostate Cancer Diagnostics Revenue by Country
11.6.1 Asia Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Prostate Cancer Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Prostate Cancer Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Prostate Cancer Diagnostics Revenue (2019-2030)
12.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Prostate Cancer Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Prostate Cancer Diagnostics Revenue by Country
12.6.1 MEALA Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Prostate Cancer Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Prostate Cancer Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Prostate Cancer Diagnostics Market by Type
1.2.1 Global Prostate Cancer Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 Prostate Cancer Diagnostics Market by Application
1.3.1 Global Prostate Cancer Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Age Below
1.3.3 Age 55-75
1.3.4 Age Above
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
2.1 Prostate Cancer Diagnostics Industry Trends
2.2 Prostate Cancer Diagnostics Industry Drivers
2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
2.4 Prostate Cancer Diagnostics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
3.2 Global Prostate Cancer Diagnostics Growth Trends by Region
3.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Prostate Cancer Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Prostate Cancer Diagnostics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Prostate Cancer Diagnostics Revenue by Players
4.1.1 Global Prostate Cancer Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Prostate Cancer Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
4.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
4.5 Global Prostate Cancer Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier
5 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY TYPE
5.1 Global Prostate Cancer Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Prostate Cancer Diagnostics Revenue by Type (2019-2030)
5.3 Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2030)
6 PROSTATE CANCER DIAGNOSTICS MARKET SIZE BY APPLICATION
6.1 Global Prostate Cancer Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Prostate Cancer Diagnostics Revenue by Application (2019-2030)
6.3 Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 OPKO
7.1.1 OPKO Comapny Information
7.1.2 OPKO Business Overview
7.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
7.1.5 OPKO Recent Developments
7.2 Genomic Health
7.2.1 Genomic Health Comapny Information
7.2.2 Genomic Health Business Overview
7.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
7.2.5 Genomic Health Recent Developments
7.3 Abbott
7.3.1 Abbott Comapny Information
7.3.2 Abbott Business Overview
7.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
7.3.5 Abbott Recent Developments
7.4 Beckman Coulter
7.4.1 Beckman Coulter Comapny Information
7.4.2 Beckman Coulter Business Overview
7.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
7.4.5 Beckman Coulter Recent Developments
7.5 Siemens Healthcare
7.5.1 Siemens Healthcare Comapny Information
7.5.2 Siemens Healthcare Business Overview
7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
7.5.5 Siemens Healthcare Recent Developments
7.6 bioMeriux
7.6.1 bioMeriux Comapny Information
7.6.2 bioMeriux Business Overview
7.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
7.6.5 bioMeriux Recent Developments
7.7 Roche
7.7.1 Roche Comapny Information
7.7.2 Roche Business Overview
7.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
7.7.5 Roche Recent Developments
7.8 MDx Health
7.8.1 MDx Health Comapny Information
7.8.2 MDx Health Business Overview
7.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
7.8.5 MDx Health Recent Developments
7.9 DiaSorin
7.9.1 DiaSorin Comapny Information
7.9.2 DiaSorin Business Overview
7.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
7.9.5 DiaSorin Recent Developments
7.10 Myriad Genetics
7.10.1 Myriad Genetics Comapny Information
7.10.2 Myriad Genetics Business Overview
7.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
7.10.5 Myriad Genetics Recent Developments
7.11 Ambry Genetics
7.11.1 Ambry Genetics Comapny Information
7.11.2 Ambry Genetics Business Overview
7.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
7.11.5 Ambry Genetics Recent Developments
8 NORTH AMERICA
8.1 North America Prostate Cancer Diagnostics Revenue (2019-2030)
8.2 North America Prostate Cancer Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Prostate Cancer Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Prostate Cancer Diagnostics Revenue by Type (2025-2030)
8.3 North America Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Prostate Cancer Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Prostate Cancer Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Prostate Cancer Diagnostics Revenue by Application (2025-2030)
8.5 North America Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Prostate Cancer Diagnostics Revenue by Country
8.6.1 North America Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Prostate Cancer Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Prostate Cancer Diagnostics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Prostate Cancer Diagnostics Revenue (2019-2030)
9.2 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Prostate Cancer Diagnostics Revenue by Type (2025-2030)
9.3 Europe Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Prostate Cancer Diagnostics Revenue by Application (2025-2030)
9.5 Europe Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Prostate Cancer Diagnostics Revenue by Country
9.6.1 Europe Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Prostate Cancer Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Prostate Cancer Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Prostate Cancer Diagnostics Revenue (2019-2030)
10.2 China Prostate Cancer Diagnostics Revenue by Type (2019-2030)
10.2.1 China Prostate Cancer Diagnostics Revenue by Type (2019-2024)
10.2.2 China Prostate Cancer Diagnostics Revenue by Type (2025-2030)
10.3 China Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
10.4 China Prostate Cancer Diagnostics Revenue by Application (2019-2030)
10.4.1 China Prostate Cancer Diagnostics Revenue by Application (2019-2024)
10.4.2 China Prostate Cancer Diagnostics Revenue by Application (2025-2030)
10.5 China Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Prostate Cancer Diagnostics Revenue (2019-2030)
11.2 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Prostate Cancer Diagnostics Revenue by Type (2025-2030)
11.3 Asia Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Prostate Cancer Diagnostics Revenue by Application (2025-2030)
11.5 Asia Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Prostate Cancer Diagnostics Revenue by Country
11.6.1 Asia Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Prostate Cancer Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Prostate Cancer Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Prostate Cancer Diagnostics Revenue (2019-2030)
12.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Prostate Cancer Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Prostate Cancer Diagnostics Revenue by Country
12.6.1 MEALA Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Prostate Cancer Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Prostate Cancer Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Tumor Biomarker Tests Major Manufacturers
Table 2. Imaging Major Manufacturers
Table 3. Biopsy Major Manufacturers
Table 4. Other Major Manufacturers
Table 5. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Age Below 55 Major Manufacturers
Table 7. Age 55-75 Major Manufacturers
Table 8. Age Above 75 Major Manufacturers
Table 9. Prostate Cancer Diagnostics Industry Trends
Table 10. Prostate Cancer Diagnostics Industry Drivers
Table 11. Prostate Cancer Diagnostics Industry Opportunities and Challenges
Table 12. Prostate Cancer Diagnostics Industry Restraints
Table 13. Global Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Prostate Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Prostate Cancer Diagnostics Market Share by Region (2019-2024)
Table 16. Global Prostate Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Prostate Cancer Diagnostics Market Share by Region (2025-2030)
Table 18. Global Prostate Cancer Diagnostics Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
Table 20. Global Prostate Cancer Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
Table 22. Global Prostate Cancer Diagnostics Players, Product Type & Application
Table 23. Global Prostate Cancer Diagnostics Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Prostate Cancer Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Prostate Cancer Diagnostics Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Prostate Cancer Diagnostics Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. OPKO Company Information
Table 37. OPKO Business Overview
Table 38. OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. OPKO Prostate Cancer Diagnostics Product Portfolio
Table 40. OPKO Recent Development
Table 41. Genomic Health Company Information
Table 42. Genomic Health Business Overview
Table 43. Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Genomic Health Prostate Cancer Diagnostics Product Portfolio
Table 45. Genomic Health Recent Development
Table 46. Abbott Company Information
Table 47. Abbott Business Overview
Table 48. Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Abbott Prostate Cancer Diagnostics Product Portfolio
Table 50. Abbott Recent Development
Table 51. Beckman Coulter Company Information
Table 52. Beckman Coulter Business Overview
Table 53. Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
Table 55. Beckman Coulter Recent Development
Table 56. Siemens Healthcare Company Information
Table 57. Siemens Healthcare Business Overview
Table 58. Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
Table 60. Siemens Healthcare Recent Development
Table 61. bioMeriux Company Information
Table 62. bioMeriux Business Overview
Table 63. bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. bioMeriux Prostate Cancer Diagnostics Product Portfolio
Table 65. bioMeriux Recent Development
Table 66. Roche Company Information
Table 67. Roche Business Overview
Table 68. Roche Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Roche Prostate Cancer Diagnostics Product Portfolio
Table 70. Roche Recent Development
Table 71. MDx Health Company Information
Table 72. MDx Health Business Overview
Table 73. MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. MDx Health Prostate Cancer Diagnostics Product Portfolio
Table 75. MDx Health Recent Development
Table 76. DiaSorin Company Information
Table 77. DiaSorin Business Overview
Table 78. DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. DiaSorin Prostate Cancer Diagnostics Product Portfolio
Table 80. DiaSorin Recent Development
Table 81. Myriad Genetics Company Information
Table 82. Myriad Genetics Business Overview
Table 83. Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
Table 85. Myriad Genetics Recent Development
Table 86. Ambry Genetics Company Information
Table 87. Ambry Genetics Business Overview
Table 88. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
Table 90. Ambry Genetics Recent Development
Table 91. North America Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 92. North America Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 93. North America Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 94. North America Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 95. North America Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 96. Europe Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 97. Europe Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 98. Europe Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 99. Europe Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 100. Europe Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 101. China Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 102. China Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 103. Asia Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 104. Asia Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 105. Asia Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. Asia Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 107. Asia Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 108. MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 109. MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 110. MEALA Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. MEALA Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 112. MEALA Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 113. Research Programs/Design for This Report
Table 114. Authors List of This Report
Table 115. Secondary Sources
Table 116. Primary Sources
Table 1. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Tumor Biomarker Tests Major Manufacturers
Table 2. Imaging Major Manufacturers
Table 3. Biopsy Major Manufacturers
Table 4. Other Major Manufacturers
Table 5. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 6. Age Below 55 Major Manufacturers
Table 7. Age 55-75 Major Manufacturers
Table 8. Age Above 75 Major Manufacturers
Table 9. Prostate Cancer Diagnostics Industry Trends
Table 10. Prostate Cancer Diagnostics Industry Drivers
Table 11. Prostate Cancer Diagnostics Industry Opportunities and Challenges
Table 12. Prostate Cancer Diagnostics Industry Restraints
Table 13. Global Prostate Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Prostate Cancer Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Prostate Cancer Diagnostics Market Share by Region (2019-2024)
Table 16. Global Prostate Cancer Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Prostate Cancer Diagnostics Market Share by Region (2025-2030)
Table 18. Global Prostate Cancer Diagnostics Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
Table 20. Global Prostate Cancer Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
Table 22. Global Prostate Cancer Diagnostics Players, Product Type & Application
Table 23. Global Prostate Cancer Diagnostics Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Prostate Cancer Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Prostate Cancer Diagnostics Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Prostate Cancer Diagnostics Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. OPKO Company Information
Table 37. OPKO Business Overview
Table 38. OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. OPKO Prostate Cancer Diagnostics Product Portfolio
Table 40. OPKO Recent Development
Table 41. Genomic Health Company Information
Table 42. Genomic Health Business Overview
Table 43. Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Genomic Health Prostate Cancer Diagnostics Product Portfolio
Table 45. Genomic Health Recent Development
Table 46. Abbott Company Information
Table 47. Abbott Business Overview
Table 48. Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Abbott Prostate Cancer Diagnostics Product Portfolio
Table 50. Abbott Recent Development
Table 51. Beckman Coulter Company Information
Table 52. Beckman Coulter Business Overview
Table 53. Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
Table 55. Beckman Coulter Recent Development
Table 56. Siemens Healthcare Company Information
Table 57. Siemens Healthcare Business Overview
Table 58. Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
Table 60. Siemens Healthcare Recent Development
Table 61. bioMeriux Company Information
Table 62. bioMeriux Business Overview
Table 63. bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. bioMeriux Prostate Cancer Diagnostics Product Portfolio
Table 65. bioMeriux Recent Development
Table 66. Roche Company Information
Table 67. Roche Business Overview
Table 68. Roche Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Roche Prostate Cancer Diagnostics Product Portfolio
Table 70. Roche Recent Development
Table 71. MDx Health Company Information
Table 72. MDx Health Business Overview
Table 73. MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. MDx Health Prostate Cancer Diagnostics Product Portfolio
Table 75. MDx Health Recent Development
Table 76. DiaSorin Company Information
Table 77. DiaSorin Business Overview
Table 78. DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. DiaSorin Prostate Cancer Diagnostics Product Portfolio
Table 80. DiaSorin Recent Development
Table 81. Myriad Genetics Company Information
Table 82. Myriad Genetics Business Overview
Table 83. Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
Table 85. Myriad Genetics Recent Development
Table 86. Ambry Genetics Company Information
Table 87. Ambry Genetics Business Overview
Table 88. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
Table 90. Ambry Genetics Recent Development
Table 91. North America Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 92. North America Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 93. North America Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 94. North America Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 95. North America Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 96. Europe Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 97. Europe Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 98. Europe Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 99. Europe Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 100. Europe Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 101. China Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 102. China Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 103. Asia Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 104. Asia Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 105. Asia Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 106. Asia Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 107. Asia Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 108. MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2024) & (US$ Million)
Table 109. MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2024) & (US$ Million)
Table 110. MEALA Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. MEALA Prostate Cancer Diagnostics Revenue by Country (2019-2024) & (US$ Million)
Table 112. MEALA Prostate Cancer Diagnostics Revenue by Country (2025-2030) & (US$ Million)
Table 113. Research Programs/Design for This Report
Table 114. Authors List of This Report
Table 115. Secondary Sources
Table 116. Primary Sources
LIST OF FIGURES
Figure 1. Prostate Cancer Diagnostics Product Picture
Figure 2. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Prostate Cancer Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 4. Tumor Biomarker Tests Picture
Figure 5. Imaging Picture
Figure 6. Biopsy Picture
Figure 7. Other Picture
Figure 8. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 9. Global Prostate Cancer Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 10. Age Below 55 Picture
Figure 11. Age 55-75 Picture
Figure 12. Age Above 75 Picture
Figure 13. Global Prostate Cancer Diagnostics Market Size (US$ Million) & (2019-2030)
Figure 14. Global Prostate Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Prostate Cancer Diagnostics Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Prostate Cancer Diagnostics Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2030)
Figure 21. Global Prostate Cancer Diagnostics Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2030)
Figure 24. North America Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 27. North America Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 29. North America Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 30. United States Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 35. Europe Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 37. Europe Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 38. Germany Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 47. China Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 49. Asia Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 52. Asia Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 54. Asia Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 55. Japan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 64. MEALA Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 66. MEALA Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 67. Mexico Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
Figure 1. Prostate Cancer Diagnostics Product Picture
Figure 2. Global Prostate Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Prostate Cancer Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 4. Tumor Biomarker Tests Picture
Figure 5. Imaging Picture
Figure 6. Biopsy Picture
Figure 7. Other Picture
Figure 8. Global Prostate Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 9. Global Prostate Cancer Diagnostics Market Size Share 2019 VS 2023 VS 2030
Figure 10. Age Below 55 Picture
Figure 11. Age 55-75 Picture
Figure 12. Age Above 75 Picture
Figure 13. Global Prostate Cancer Diagnostics Market Size (US$ Million) & (2019-2030)
Figure 14. Global Prostate Cancer Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Prostate Cancer Diagnostics Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Prostate Cancer Diagnostics Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Prostate Cancer Diagnostics Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2030)
Figure 21. Global Prostate Cancer Diagnostics Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2030)
Figure 24. North America Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 27. North America Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 29. North America Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 30. United States Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 35. Europe Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 37. Europe Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 38. Germany Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 47. China Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 49. Asia Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 52. Asia Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 54. Asia Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 55. Japan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 61. MEALA Prostate Cancer Diagnostics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 62. MEALA Prostate Cancer Diagnostics Revenue by Type (2025-2030) & (US$ Million)
Figure 63. MEALA Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
Figure 64. MEALA Prostate Cancer Diagnostics Revenue by Application (2025-2030) & (US$ Million)
Figure 65. MEALA Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
Figure 66. MEALA Prostate Cancer Diagnostics Revenue Share by Country (2019-2030)
Figure 67. Mexico Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 68. South Korea Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 69. Brazil Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 70. Israel Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 71. Argentina Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 72. Colombia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 73. Turkey Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 74. Saudi Arabia Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 75. UAE Prostate Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 76. Years Considered
Figure 77. Research Process
Figure 78. Key Executives Interviewed
